Lilly-Lupin Bolster India Alliance But Cialis Faces Crowded Market
Executive Summary
Eli Lilly and Lupin are building on their alliance in India, with Lupin introducing Lilly’s Cialis (tadalafil) – a teeming market awaits the product, however.
You may also be interested in...
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
Lilly-Lupin link revs up Indian diabetes
A string of new marketing deals is set to redefine competition in the growing Indian diabetes market. The latest alliance involves Lilly and Lupin, where the Indian firm will promote and distribute Lilly's Huminsulin range in India and Nepal, doubling doctor reach for the insulin products to about 45,000 almost overnight.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.